Analgesic and anti-hyperalgesic effects of muscle injections with lidocaine or saline in patients with fibromyalgia syndrome
Article first published online: 5 NOV 2013
© 2013 European Pain Federation - EFIC®
European Journal of Pain
Volume 18, Issue 6, pages 803–812, July 2014
How to Cite
Staud, R., Weyl, E.E., Bartley, E., Price, D.D. and Robinson, M.E. (2014), Analgesic and anti-hyperalgesic effects of muscle injections with lidocaine or saline in patients with fibromyalgia syndrome. European Journal of Pain, 18: 803–812. doi: 10.1002/j.1532-2149.2013.00422.x
This study was supported by NIH grant AR053541, 1 R01 NR014049-01 and in part by NIH National Center for Advancing Translational Sciences (NCATS) grant UL1 TR000064.
Conflicts of interest
- Issue published online: 8 MAY 2014
- Article first published online: 5 NOV 2013
- Manuscript Accepted: 5 OCT 2013
- NIH. Grant Numbers: AR053541, 1 R01 NR014049-01, UL1 TR000064
Patients with musculoskeletal pain syndrome including fibromyalgia (FM) complain of chronic pain from deep tissues including muscles. Previous research suggests the relevance of impulse input from deep tissues for clinical FM pain. We hypothesized that blocking abnormal impulse input with intramuscular lidocaine would decrease primary and secondary hyperalgesia and FM patients' clinical pain.
We enrolled 62 female patients with FM into a double-blind controlled study of three groups who received 100 or 200 mg of lidocaine or saline injections into both trapezius and gluteal muscles. Study variables included pressure and heat hyperalgesia as well as clinical pain. In addition, placebo factors like patients' anxiety and expectation for pain relief were used as predictors of analgesia.
Primary mechanical hyperalgesia at the shoulders and buttocks decreased significantly more after lidocaine than saline injections (p = 0.004). Similar results were obtained for secondary heat hyperalgesia at the arms (p = 0.04). After muscle injections, clinical FM pain significantly declined by 38% but was not statistically different between lidocaine and saline conditions. Placebo-related analgesic factors (e.g., patients' expectations of pain relief) accounted for 19.9% of the variance of clinical pain after the injections. Injection-related anxiety did not significantly contribute to patient analgesia.
These results suggest that muscle injections can reliably reduce clinical FM pain, and that peripheral impulse input is required for the maintenance of mechanical and heat hyperalgesia of patients with FM. Whereas the effects of muscle injections on hyperalgesia were greater for lidocaine than saline, the effects on clinical pain were similar for both injectates.